February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

February 12, 2026

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Conexiant

February 12, 2026

Abortion and Breast Cancer: Any Link?

Analysis of more than 30,000 breast cancer cases finds no increased risk of breast cancer following induced abortion or miscarriage

Conexiant

February 12, 2026

Leukemia Case Prompts Broader Review

Researchers assess hematologic malignancies temporally associated with mRNA COVID-19 vaccination.

Conexiant

February 12, 2026

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

Conexiant

February 10, 2026

Why Scientists Are Revisiting a Polarizer

The nation’s top cancer institute takes a closer look at a disputed drug.

KFF Health News

February 09, 2026

Dupilumab and Lymphoma Risk in AD?

Dupilumab is safe from a lymphoma-risk perspective in atopic dermatitis and other type 2 inflammatory diseases, based on real-world data.

Conexiant

February 06, 2026

Tracking Opioid Refills After Surgery

Researchers evaluated perioperative and postdischarge factors associated with opioid refill prescriptions during the first 90 days after inpatient otolaryngology–head and neck surgery.

Conexiant

February 06, 2026

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection

Conexiant